|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Net loss | |||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | |||||
| Net loss | |||||
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | |||||
| Goodwill impairment | |||||
| Intangibles impairment | |||||
| Lease impairment | |||||
| Goodwill and Intangible impairment | |||||
| Stock-based compensation | |||||
| Depreciation and amortization | |||||
| Depreciation, amortization | |||||
| Defined benefit plan obligation and other | |||||
| Loss (gain) on disposal of property and equipment | |||||
| Interest added to convertible note payable | |||||
| Interest expense for reduction in convertible note conversion price | |||||
| Amortization of debt discount and warrant modification | |||||
| Loss on equity financing | |||||
| Gain on change in fair value of warrant liabilities | |||||
| Interest added to convertible note payable | |||||
| Interest expense for reduction in convertible note conversion price | |||||
| Amortization of debt discount and warrant modification | |||||
| Loss on equity financing | |||||
| Fair Value Adjustment of Warrants | |||||
| Loss on debt extinguishment | |||||
| Changes in assets and liabilities: | |||||
| Accounts receivable | |||||
| Inventories | |||||
| Prepaid expenses and other current assets | |||||
| Accounts payable | |||||
| Accrued liabilities and other liabilities | |||||
| Contract liabilities | |||||
| Other | |||||
| Net cash used in operating activities | |||||
| CASH FLOW FROM INVESTING ACTIVITIES: | |||||
| Purchases of property and equipment | |||||
| Proceeds from the sale of property and equipment | |||||
| Capitalization of platform development costs | |||||
| Capitalization of internal-use software costs | |||||
| Net cash used in investing activities | |||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | |||||
| Proceeds from the sale of Common Stock and warrant liabilities | |||||
| Proceeds from exercise of warrants | |||||
| Series B Warrants | |||||
| Series F Warrants | |||||
| Series F Convertible Preferred Stock | |||||
| Total proceeds from exercise of warrants | |||||
| Gross proceeds | |||||
| Proceeds from the sale of preferred stock and warrants | |||||
| Series F Preferred Stock and Warrants | |||||
| Series G Convertible Preferred Stock | |||||
| Total proceeds from the sale of preferred stock and warrants | |||||
| Repayments on COVID loans | |||||
| Payments on convertible note | |||||
| Repayments on other short-term loan | |||||
| Issuance costs for sale of Series F preferred stock and warrants | |||||
| Series F Convertible Preferred Stock | |||||
| Total issuance costs for sale of Series F preferred stock and warrants | |||||
| Net cash provided by financing activities | |||||
| Net change in cash | |||||
| Cash at beginning of year | |||||
| Cash at end of year | |||||
| Effects of foreign exchange rates on cash flows | |||||
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | |||||
| Interest cash paid | |||||
| Right-of-use asset and liability | |||||
| Conversion of Preferred Stock, Series F Convertible to Common Stock | |||||
| Dividends on Series F Preferred Stock | |||||
| Deemed dividend on Series F Preferred stock and warrant | |||||
| Principal on convertible note converted to common stock | |||||
| Alternate cashless exercise of Series A Warrants | |||||
| Income taxes paid | |||||
| NON-CASH INVESTING AND FINANCING ACTIVITIES: | |||||
| Conversion of stock | |||||
| Conversion of Series F Preferred Stock into Common Stock | |||||
| Conversions of Series G Preferred Stock Into Common Stock | |||||
| Conversion of Series F Warrants to Common Stock | |||||
| Stock issued | |||||
| Series A Warrants | |||||
| Restricted Common Stock | |||||
| Conversion of Convertible Note | |||||
| Accrued dividends on Series F Preferred Stock | |||||
| Deemed dividends on Series F and G Preferred Stock, Series B and F Warrants and warrant exchange | |||||
| Accrued expense settled with Series B Warrant exercise | |||||
| Series B Warrants | |||||
| Total accrued expense settled with Series B Warrant exercise | |||||
Loading...